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effects of interferons and viruses  
on Metabolism
Stephanie Deborah Fritsch and Thomas Weichhart*
Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria
Interferons (IFNs) are potent pleiotropic cytokines that broadly alter cellular functions 
in response to viral and other infections. These alterations include changes in protein 
synthesis, proliferation, membrane composition, and the nutritional microenvironment. 
Recent evidence suggests that antiviral responses are supported by an IFN-induced 
rewiring of the cellular metabolism. In this review, we discuss the roles of type I and type 
II IFNs in regulating the cellular metabolism and biosynthetic reactions. Furthermore, we 
give an overview of how viruses themselves affect these metabolic activities to promote 
their replication. In addition, we focus on the lipid as well as amino acid metabolisms, 
through which IFNs exert potent antiviral and immunomodulatory activities. Conversely, 
the expression of IFNs is controlled by the nutrient sensor mammalian target of rapa-
mycin or by direct reprograming of lipid metabolic pathways. These findings establish a 
mutual relationship between IFN production and metabolic core processes.
Keywords: glycolysis, oxidative phosphorylation, fatty acid synthesis, fatty acid oxidation, cholesterol synthesis, 
mTOR, immunometabolism
iNTRODUCTiON
Type I and II interferons (IFNs) are important cytokines that are induced upon viral infections 
(1). They promote a so-called “antiviral state” that limits viral replication in infected cells and viral 
spreading in non-infected cells. Additionally, IFNs are expressed during bacterial infections or 
autoimmune diseases and exert potent immunomodulatory functions. The human type I IFN family 
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5-adenosine monophosphate-activated protein kinase; ATP, adenosine triphosphate; cGAS, cyclic guanosine monophosphate-
adenosine monophosphate synthase; ER, endoplasmic reticulum; F6P, fructose-6-phosphate; FA, fatty acid; FADH2, flavin 
adenine dinucleotide; FAO, fatty acid oxidation; FAS, fatty acid synthesis; G6P, glucose-6-phosphate; Glut4, glucose transporter 
4; HBV, hepatitis B virus; HCMV, human cytomegalovirus; HCV, hepatitis C virus; Hif1α, hypoxia-inducible factor 1α; HIV, 
human immunodeficiency virus; HSV1, herpes simplex virus; H2O2, hydrogen peroxide; IDO1, indoleamine-2,3-dioxygenase 
1; IFN, interferon; IFNAR1/2, interferon alpha and beta receptor subunit 1/2; IFNR, interferon receptor; IL-1, interleukin-1; 
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consists of 13 IFNα subtypes (14 in mice), one single IFNβ gene, 
and some further poorly analyzed genes (2). The sole representa-
tive of class II IFN is IFNγ, which is mainly produced by T cells 
and NK cells (2). IFNγ generally activates innate responses by 
augmenting inflammatory cytokine and chemokine production, 
microbial killing, and antigen presentation of macrophages and 
dendritic cells (3). Upon stimulation of extra- and intracellular 
pattern recognition receptors (PRR), including Toll-like recep-
tors (TLR), nucleotide-binding oligomerization domain-like 
receptors, and retinoic acid-inducible gene I-like receptors, many 
immune cells, but also non-hematopoietic cells, are capable of 
inducing type I IFNs by a concerted activation of transcription 
factors called IFN-regulatory factors (IRFs) (4). Expression of 
IFNs is also dependent on the sensing of the extra- and intracel-
lular microenvironment by the mammalian target of rapamycin 
(mTOR) network (5). mTOR complex 1 (mTORC1) integrates 
the main classes of nutrients and energy sources [amino acids, 
glucose, lipids, and adenosine triphosphate (ATP)] to couple 
the environmental status with cellular activation and translation 
(5). Activation of mTORC1 is required to induce the translation 
as well as the activation of IRFs, including IRF5 and IRF7, to 
maximize type I IFN production (6–9). IFNα and IFNβ bind a 
heterodimeric membrane receptor consisting of the interferon 
alpha and beta receptor subunit 1 (IFNAR1) and IFNAR2 (10). 
Receptor engagement activates the receptor-associated protein 
tyrosine kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 
(TYK2), which phosphorylate and activate the transcription fac-
tors signal transducer and activator of transcription 1 (STAT1) 
and STAT2 (10). In contrast, the dimeric IFNγ receptor consists 
of the interferon gamma receptor 1 (IFNGR1) and IFNGR2 and 
activates the receptor-associated tyrosine kinases, JAK1 and 
JAK2, which solely activate STAT1 (11).
Type I IFNs and IFNγ induce the transcriptional upregulation 
of several hundred interferon stimulated genes (ISGs) (1, 4). Three 
families of ISGs have been extensively studied with respect to 
their antiviral activities. These genes encode the double-stranded 
RNA-activated protein kinase (PKR), the 2′,5′-oligoadenylate 
synthetases (OAS), and the Mx protein(s) (1, 12). They actively 
participate in inhibiting viral replication by different mecha-
nisms. PKR is an IFN-inducible and RNA-dependent kinase that 
phosphorylates the translation initiation factor 2α (eIF2α), which 
inhibits cellular and viral translation (13). Activation of OAS by 
binding of dsRNA stimulates RNase L activity, which cleaves 
cellular and viral ssRNA to inhibit protein expression (13). Mx 
proteins are GTPases that often associate with nucleocapsid-like 
viral structures to trap and inhibit viral replication (14).
This review focuses on additional roles of IFNs involving the 
regulation of the cellular metabolism. The following sections dis-
cuss recent evidence and older observations of how type I and II 
IFNs modulate metabolic pathways to generate an antiviral state 
and influence subsequent immune responses.
CeLLULAR MeTABOLiSM
The principal purpose of metabolism is the conversion of nutri-
ents to energy to maintain all cellular processes and the delivery 
of building blocks for the biosynthesis of proteins, lipids, nucleic 
acids, and some carbohydrates. Viruses are incapable of metabo-
lizing on their own and are, therefore, completely dependent upon 
host metabolism. Their life cycle requires an energy-demanding 
synthesis of high levels of proteins, glycoproteins, nucleic acids, 
and sometimes lipids. Therefore, there is a mutual relationship 
between viral replication, metabolism, and host defense. First, we 
will discuss the basic principles of metabolism. Afterward, we will 
continue to elaborate on specific pathways of metabolism that are 
affected by IFNs or viral infection.
energy Metabolism
The central nutrients, used by eukaryotic cells to generate energy 
in the form of ATP, are carbohydrates, amino acids, and fatty acids 
(FAs) (15). In the presence of oxygen, non-proliferating cells take 
up the carbohydrate glucose and metabolize it in the cytoplasm 
to pyruvate through a process called glycolysis (Figure 1). This 
results in a net production of two ATPs and  the reduction of two 
nicotinamide adenine dinucleotide (NAD) molecules to NADH. 
Pyruvate can be transported into the mitochondria, where it is 
oxidized into acetyl coenzyme A (acetyl-CoA) with the produc-
tion of one molecule of carbon dioxide and one more NADH. 
Acetyl-CoA acts as fuel for the tricarboxylic acid (TCA) cycle 
(also known as citric acid or Krebs cycle), through which it is 
completely oxidized to carbon dioxide with the net production 
of three molecules of NADH, one molecule of ATP (or guano-
sine triphosphate GTP), and one molecule of the reduced form 
of flavin adenine dinucleotide (FADH2) (15). The molecules of 
NADH and FADH2, generated until this point, are the inputs for 
the electron transport chain. They are used to establish a proton 
gradient at the inner mitochondrial membrane, which finally 
generates ATP from adenosine diphosphate in a process called 
oxidative phosphorylation (16) (Figure 1). In summary, from one 
molecule of glucose, theoretically, 36 equivalents of ATP can be 
generated in eukaryotes, although due to proton leakage and inef-
ficiencies of the ATPase, the observed yield is about 30 ATPs (17). 
Importantly, glucose is not the only energy source, which can be 
used by eukaryotic cells. The amino acid glutamine is a second 
carbon source that can be converted to α-ketoglutarate (αKG) as 
oxidative substrate to fuel the TCA cycle (16, 18). Moreover, fatty 
acid oxidation (FAO) in the mitochondria generates acetyl-CoA, 
NADH, and FADH2, which are further used to generate ATP (19). 
FAs are the most energetic nutrients, yielding the highest levels of 
ATP on an energy per gram basis. Hence, glycolysis and the TCA 
cycle are the central cellular respiratory systems of eukaryotic 
cells (15).
Anabolic Metabolism
When cells start to proliferate, there is increasing demand of 
nutrients for energy production as well as biosynthesis of novel 
molecules (20). Therefore, proliferating cells increase glucose 
uptake and glycolysis, but do not oxidize all of the additional 
glucose-derived pyruvate in the TCA cycle. Instead, the pyruvate 
is reduced to lactate despite the presence of oxygen, which is 
therefore called aerobic glycolysis (21) (Figure 1). This effect was 
first described in tumor cells by Otto Warburg and is now called 
FiGURe 1 | energy and biosynthetic metabolism. Glucose is taken up and metabolized in the cytoplasm to pyruvate in a process called glycolysis. Pyruvate is 
then transported into the mitochondria and oxidized into acetyl coenzyme A (acetyl-CoA), which enters the tricarboxylic acid (TCA) cycle. The molecules NADH and 
FADH2 produced until this point are the inputs for the electron transport chain. Another important energy source are fatty acids, whose oxidation delivers acetyl-coA. 
Aerobic glycolysis takes place in proliferating (and cancer) cells and describes the phenomenon of increased glucose uptake and glycolysis with the subsequent 
production of lactate. Glutamine is another carbon source that can be transformed to αKG and, therefore, enters the TCA cycle. Glutamine can also be used as 
nitrogen donor in the hexosamine pathway, which requires F6P and is important for N-glycosylation of proteins. G6P can feed into the pentose phosphate pathway, 
which is important for the production of nucleotides and NADPH. Mitochondrial citrate can enter the cytoplasm and feeds into de novo fatty acid synthesis. For 
further details consult the text.
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the Warburg effect (22). It is important to note that TCA flux is 
reduced but maintained during aerobic glycolysis in proliferating 
cells. Although aerobic glycolysis generates only two molecules of 
ATP, it is thought to generate cellular building blocks for rapidly 
proliferating cells (15). However, also amino acids are important 
contributors to increased cell mass in proliferating cells (23). Many 
glycolytic intermediates provide backbone carbons for multiple 
non-essential amino acids or function as substrates for the bio-
synthesis of phospholipids and triacylglycerols. In addition, the 
glycolytic intermediate glucose-6-phosphate (G6P) can feed into 
the pentose phosphate pathway to generate ribose-5-phosphate, 
which is important for nucleotide biosynthesis as well as the 
conversion of nicotinamide adenine dinucleotide phosphate to 
its reduced form NADPH (Figure 1). NADPH is used as reduc-
ing agent in lipid or nucleic acid synthesis and protects against 
cellular oxidative stress by generating reduced glutathione that 
inactivates reactive oxygen species (ROS) (e.g., H2O2) and free 
radicals (16). αKG, derived from glutamine, can be metabolized 
to malate and then to pyruvate to support NADPH generation 
in a process called glutaminolysis (16). Furthermore, glutamine 
is used as nitrogen donor for the biosynthesis of nucleotides, 
non-essential amino acids, and hexosamines. The hexosamine 
pathway requires fructose-6-phosphate (F6P) from glycolysis and 
acetyl-CoA, in addition to glutamine to produce uridine diphos-
phate-N-acetylglucosamine (UDP-GlcNAc), which is important 
for N-glycosylation of proteins (24). Therefore, N-glycosylation 
represents a nutrient-sensitive protein modification, which regu-
lates the glycosylation of IFNs and viral glycoproteins (25). This 
modification is involved in protein trafficking, in viral entry, and 
in evading the immune system’s detection by some viruses (26).
As described above, during aerobic glycolysis, the TCA cycle 
is sustained in proliferating cells by glucose-derived pyruvate, as 
well as by replenishing depleted intermediates in the form of, e.g., 
glutamine in a process called anaplerosis (27, 28). The TCA cycle 
FiGURe 2 | effects of interferons (iFNs) on energy and lipid metabolism. Type I IFNs promote glycolysis while mitochondrial respiration is regulated cell-type 
specifically. Citrate can induce the formation of itaconic acid or acetyl coenzyme A (acetyl-CoA). Itaconic acid is a bactericidal metabolite, which inhibits 
proinflammatory cytokine expression and mitochondrial respiration. Acetyl-CoA can either promote NO and reactive oxygen species (ROS) production or initiate fatty 
acid (FA) and cholesterol synthesis. As viral replication is an energy-demanding process, which depends on protein and nucleotide synthesis, most viral infections 
enhance FA and cholesterol synthesis, which, on the other hand, can be reduced by adenosine monophosphate-activated protein kinase and statins. 25-HC is a 
soluble antiviral factor that broadly inhibits growth of many enveloped viruses by inhibiting sterol regulatory binding protein and enhances membrane rigidity. IFNs 
also promote subsequent NO and ROS production. For further details consult the text.
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contributes many intermediates that act as biosynthetic substrates. 
For example, mitochondrial citrate can feed into de novo FA and 
cholesterol synthesis upon its export to the cytoplasm, where it 
is converted to acetyl-CoA and oxaloacetate by ATP citrate lyase 
(ACLY). Cytoplasmic acetyl-CoA is then the substrate for FAs, 
cholesterol, and isoprenoid synthesis (Figure 1). Phospholipids 
are generated from FAs and, together with cholesterol, form 
the majority of the lipid bilayers of the cellular membranes. 
Oxaloacetate is further metabolized to yield αKG and NADPH 
(29). Alternatively, oxaloacetate can be transaminated to aspar-
tate, which acts as a carbon source in nucleotide biosynthesis. In 
addition, ACLY-derived acetyl-CoA and oxaloacetate can serve 
as precursors for nitric oxide (NO) and ROS production (30, 31).
eFFeCTS OF iFNs ON eNeRGY 
MeTABOLiSM
While it has been known for a long time that viral infections and 
IFNs interfere with lipid metabolism including FA and choles-
terol synthesis (described below), recent studies have shown a 
more general influence of IFNs on the energy metabolism of cells.
Generally, a theme emerges that type I IFNs promote glycolysis 
(Figure 2). For example, IFNβ stimulates a PI3K/AKT-dependent 
glucose uptake in mouse embryonic fibroblasts that may enhance 
ATP production (32). Inhibition of IFNβ-induced glycolysis with 
2-deoxyglucose (2-DG), a competitive inhibitor of hexokinase, 
the first enzyme in the glycolysis cascade, enhances replication 
of coxsackievirus B3 in  vitro (32). This suggests that enhanced 
glycolysis may support the establishment of an antiviral state. 
Similarly, injection of the synthetic dsRNA poly(I:C), a TLR3 and 
melanoma differentiation antigen 5 agonist, into mice induces an 
increase in glycolysis in splenic CD11c+ MHCII+ DCs ex vivo (33). 
This increase is dependent on IFNAR1 and thus mediated by type 
I IFNs. Increased glycolysis often is accompanied by a decreased 
oxidative consumption, and this Warburg effect depends on 
expression of hypoxia-inducible factor 1α (Hif1α) and is required 
to efficiently prime CD8+ and CD4+ T cells in  vivo (33). In 
 macrophages, TYK2 and IFNAR1 are also required for an increase 
in glycolysis-mediated lactate production (34). IRF5 increases 
glycolysis in macrophages through a glycolytic gene expression 
induced by activation of AKT2 (35). In a human squamous car-
cinoma cell line, expression of type I IFN-regulated STAT1 pro-
motes aerobic glycolysis and decreases oxidative phosphorylation, 
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which contributes to tumor growth in a xenograft model (36). 
Other studies also showed that mitochondrial respiration and 
ATP production are diminished upon type I IFN treatment in 
mouse L929 or human Daudi cells (37). In humans, IFNβ-treated 
multiple sclerosis patients exhibited a dose-dependent reduction 
of ATP levels in isolated CD4+ T cells (38).
However, there are also important examples, where type I IFN 
stimulates oxygen consumption. Plasmacytoid dendritic cells 
(pDCs) are specialized immune cells devoted to the production 
of large amounts of type I IFNs after viral recognition (39). Mouse 
pDCs upregulate oxidative phosphorylation and ATP production 
24 h after stimulation with poly(I:C) or directly after type I IFN 
treatment through an autocrine loop (40). This boost in energy 
production is required for full immune effector functions in vitro 
and for fighting lymphocytic choriomeningitis virus (LCMV) 
infection in vivo. This increase in oxidative phosphorylation and 
mitochondrial respiration is fueled by FAO (40). Interestingly, the 
FAs required for FAO seem to be a result of de novo fatty acid 
synthesis (FAS) from glycolysis-derived pyruvate. The stimulat-
ing effect of type I IFN on increased oxygen consumption was 
also observed on conventional DCs, keratinocytes, or memory 
T cells, but not on effector T cells (40). This increase in ATP and 
mitochondrial fitness may support the energetic demands of high 
cytokine production in pDCs and in non-hematopoietic cells to 
support survival during viral infection. In contrast, stimulation 
of human pDCs with influenza virus induced a Warburg-like 
remodeling of the energy metabolism, including enhanced gly-
colytic flux and decreased mitochondrial respiration (41). These 
studies in total suggest that type I IFN, by canonical pathway 
activation through IFNAR1, Tyk2, and STAT1, mediates an 
induction of glycolysis, whereas mitochondrial respiration seems 
to be regulated cell-type specifically (Figure 2). Interestingly, type 
I IFN and IFNγ induce lipolysis in cultured adipocytes and in 
mice in vivo and may thus supply cells with FAs (42). However, 
this function of IFN has not been thoroughly investigated.
A decrease in oxidative phosphorylation reduces mitochon-
drial ATP production, which may still be compensated by ATP 
produced through aerobic glycolysis, whose flux can be dramati-
cally increased when glucose is not limited (43). Reduced mito-
chondrial respiration frees TCA intermediates, which can be used 
in subsequent biosynthetic reactions. For example, activation of 
macrophages with IFNγ and lipopolysaccharide (LPS) induces 
high levels of glycolysis and a break of TCA flux. This leads to 
the accumulation of succinate and citrate in conjunction with 
induction of FAS (44). Succinate can drive mitochondrial ROS 
production (45), which is a conserved response against many 
pathogens (46) but may also cause tissue pathology (as discussed 
below) (47). Naujoks et al. showed that type I and II IFNs control 
Legionella pneumophila infection in alveolar macrophages by 
induction of a bactericidal molecule (48). In fact, Legionella-
infected macrophages induce IFN-dependent expression of 
immune-responsive gene (IRG) 1 that mediates production 
of itaconic acid (also known as methylenesuccinic acid). This 
molecule is bactericidal against a number of extracellular multi-
drug-resistant, Gram-positive, and Gram-negative bacteria (48). 
Itaconic acid is produced by IRG1 through decarboxylation of 
cis-aconitate, a TCA intermediate that is formed from citrate (49, 
50) (Figure 2). Except of being a bactericidal metabolite, itaconic 
acid also inhibits proinflammatory cytokine expression (51) and 
mitochondrial respiration (51, 52). Stimulation of macrophages 
with poly(I:C), IFNγ, or LPS can also increase the expression and 
activation of ACLY (31, 34). This, in turn, enhances the conver-
sion of citrate into acetyl-CoA and oxaloacetate, which promotes 
subsequent NO and ROS production.
MODULATiON OF LiPiD SYNTHeSiS BY 
viRUSeS AND iFNs
Viral replication depends on a massive induction of protein 
and nucleotide synthesis. Therefore, most viruses themselves 
upregulate carbon fluxes and promote efflux to nucleotide and 
amino acid biosynthesis (53). Additionally, virus entry, replica-
tion, and assembly rely on membranous networks, surrounding 
and residing within the host cells. These include the plasma, the 
endolysosomal, and the endoplasmic reticulum (ER) membranes 
(54–56), which all function as scaffolds to recruit and concen-
trate viral and host components, necessary for viral replication 
and assembly (57). Many viruses induce changes in membrane 
fluidity and a massive proliferation of membranes such as the 
ER, which is the place for translation of secretory and membrane 
proteins and for N-glycosylation (54, 55). Obviously, enveloped 
viruses need not only to induce membrane generation but also 
alter the composition of the cell membrane to meet their needs 
for effective infectious progeny particles (58). However, viral 
replication is also a highly energy-demanding process; therefore, 
utilizing all available energy to produce ATP is rate-limiting for 
some viruses (58).
FA Synthesis and iFNs
In light of these functional prerequisites, it comes as no surprise 
that most viral infections enhance FA and cholesterol synthesis 
to support generation of membranes and ATP production (53) 
(Figure  2). For example, human cytomegalovirus (HCMV) 
upregulates most metabolic pathways in infected fibroblasts 
and drives flux from glycolysis through the TCA cycle to FAS 
(59). Inhibition of FAS suppresses replication of HCMV (59). 
Mechanisms of HCMV-induced metabolic reprograming include 
the activation of the glucose transporter Glut4 and inductions 
of ACLY and acetyl coenzyme A carboxylase (ACC) (53, 60). 
After ACLY-dependent generation of acetyl-CoA in the cyto-
plasm, ACC carboxylates acetyl-CoA to malonyl-CoA, which 
is a critical rate-limiting step in FAS (19). ACLY and ACC are 
currently evaluated as therapeutic targets for cancer, obesity, 
diabetes, and viral infections (61, 62). Similarly, influenza A, 
flaviviridae family members including hepatitis C virus (HCV) 
and West Nile virus (WNV), enteroviruses including poliovirus 
and coxsackievirus B3, rotavirus, rift valley fever virus, and 
respiratory syncytial virus depend on FAS for viral replication, 
making its modulation an attractive therapeutic target (63–65). 
5′-adenosine  monophosphate-activated protein kinase gets acti-
vated after certain virus infections, such as rift valley fever virus 
or coxsackievirus B3, and potently inhibits FAS (66, 67). Some 
viruses, such as influenza A, use FAS to induce the production of 
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prostaglandin E2, which inhibits IFN expression and promotes 
apoptosis in macrophages (68). Viral replication is a highly energy-
demanding process. Therefore, utilizing all available energy is 
critical and rate-limiting for some viral infections. Hence, some 
viruses depend on FAS and their degradation by FAO to produce 
ATP. In this respect, Vaccinia virion assembly is dependent on 
ATP synthesis fueled by FAS and FAO (69). Dengue virus, on the 
other hand, induces FAO by an autophagy-dependent processing 
of lipid droplets and triglycerides to generate ATP for efficient 
replication (70). Nevertheless, dengue virus also induces FAS to 
support virus replication (71). Hence, channeling the FAs from 
biosynthesis to catabolism by the induction of FAO, as seen in 
pDCs (40), could represent a novel powerful antiviral mechanism 
of IFN. However, further work is required to elucidate whether 
this represents a general antiviral mechanism.
Cholesterol Homeostasis and iFN 
Responses
Many viruses do not only modulate FAs, but also cholesterol 
homeostasis to enhance their replication efficiency. For example, 
WNV upregulates biosynthesis of cholesterol, redistributing it 
to viral membranes in the phase of replication (72). Moreover, 
HCV, hepatitis B virus (HBV), measles, human immunodefi-
ciency virus (HIV), and dengue virus also change cholesterol 
pathway gene expression in a variety of cellular systems (73–76). 
Pharmacological disruption of cholesterol synthesis, e.g., 
by statins, often results in the inhibition of viral replication 
(77–82). Recent evidence has shown that an important antiviral 
mechanism of type I IFN seems to be inhibition of cholesterol 
and fatty acid biosynthesis derived from glucose (83, 84). Type 
I IFN reduces cholesterol synthesis upon CMV, herpes simplex 
(HSV1), semliki forest virus, vaccinia virus (VV), and adenovirus 
(ADV) infection in bone marrow-derived macrophages, which is 
dependent on IFNAR1 and TYK2 (83). Similarly, infection with 
murine gammaherpesvirus-68 (MHV-68) reduces cholesterol 
and long chain FAS in macrophages (84). It is important to note 
that total cholesterol levels are not strongly affected upon inhibi-
tion of cholesterol synthesis by IFN due to an enhancement of 
cholesterol import (84) (Figure  2). Similarly, WNV infection 
enhances cholesterol synthesis, but total cholesterol levels do not 
change (72). Inhibition of cholesterol biosynthesis has a direct 
antiviral effect. The sterol regulatory binding protein 2 (SREBP2), 
together with SREBP1, are the main transcription factors involved 
in coordinating the regulation of the sterol biosynthesis pathway 
(85). IFNs potently inhibit the transcription and expression of 
SREBP2 via IFNAR1 (83). On the other hand, WNV-induced 
redistribution of cellular cholesterol downregulates the IFN-
stimulated JAK–STAT antiviral signaling response to infection 
potentially by influencing lipid raft signaling (72).
Fascinatingly, limiting cholesterol synthesis alone induces 
spontaneous type I IFN production and enhances antiviral immu-
nity (84). Deletion of SREBP2 or the ER chaperone SCAP, which 
regulates SREBP2, reduces synthesis but enhances the uptake of 
cholesterol. This shift induces spontaneous IFN signaling that is 
strongly enhanced upon viral infection in bone marrow-derived 
macrophages or mouse embryonic fibroblasts. The IFN response 
in these cells is dependent on the cGAS–STING–TBK1–IRF3 
pathway (84). The stimulator of interferon gene (STING) protein 
is anchored on the ER and Golgi apparatus, suggesting that cho-
lesterol levels and potentially lipid rafts in these membranes may 
modulate STING signaling. Moreover, it is interesting to note that 
cyclic guanosine monophosphate-adenosine monophosphate 
synthase (cGAS), which senses DNA from viral infections, is 
evolutionarily conserved with OAS, another important antiviral 
protein that is induced by IFNs (86). In summary, many viruses 
increase cholesterol and FAS. This is counteracted by type I IFN 
signaling, which limits FA and cholesterol synthesis. Reducing 
cholesterol synthesis alone induces IFN production establishing 
an inflammatory circuit, which links the regulation of the sterol 
pathway with the antiviral IFN defense responses. However, one 
report noted enhanced cholesterol synthesis derived from acetate 
in IFNβ-treated HeLa cells (87).
Regulation of Membrane Function by 
25-Hydroxycholesterol
Cholesterol-derived metabolites such as oxysterols are important 
systemic mediators that regulate many immunological functions 
(88). IFNs or viral infections lead to the induction and secretion 
of one oxysterol in macrophages: 25-hydroxycholesterol (25-HC) 
(89) (Figure  2). 25-HC is a soluble antiviral factor, generated 
from cholesterol by IFN-dependent activation of cholesterol-
25-hydroxylase via STAT1 (89). 25-HC broadly inhibits growth of 
many enveloped viruses, such as vesicular stomatitis virus, HSV, 
HIV, MHV68, and Ebola virus, by suppressing membrane fusion 
between the virus and the host cell (90, 91). Mechanistically, 
25-HC seems to incorporate into the membrane and/or modify 
the membrane composition (91). Indeed, an IFN-dependent 
increase in plasma membrane rigidity has long been observed 
in several previous studies (92–94). IFNβ augments membrane 
rigidity already after 30 min, and this is maintained for 2 days 
making it a powerful antiviral mechanism to prevent viral infec-
tion and spreading (93, 95). Nevertheless, type I IFNs decrease 
membrane contents of saturated FAs and increase unsaturated 
FAs (92). In patients with chronic hepatitis C infection, treatment 
with IFNα2 reduces the deformability and membrane fluidity of 
red blood cells, which may result in hemolytic anemia, a frequent 
side effect of IFN therapy (96). Another downside of IFN-induced 
25-HC expression is its capacity to inhibit SREBP1, which not 
only drives FAS but also stimulates transcription of interleukin-1, 
a secreted inflammatory protein with wide-ranging antibacterial 
functions (97). This may explain why IFNs, produced during viral 
infections, enhance the subsequent susceptibility to bacterial or 
fungal infections (98–100). Generally, there is increasing aware-
ness of a close relationship between membrane lipid dynamics 
and innate immune responses (101).
AMiNO ACiD MeTABOLiSM AND iFNs
iFNs Deplete Polyamines to Restrict virus 
Replication
Polyamines are a family of small polycationic molecules, derived 
from decarboxylation of the amino acid ornithine, that classically 
comprise three molecules: putrescine, spermidine, and spermine 
FiGURe 3 | interferons and their influence on nitric oxide and polyamine metabolism. The polyamines putrescine, spermidine, and spermine derive from the 
amino acid l-arginine. One rate-limiting enzyme in polyamine synthesis is ODC, while Spermidine–spermine acetyltransferase (SAT1) is an important enzyme in 
polyamine catabolism. As polyamines are important for viral replication, SAT1 constitutes an important interferon stimulated gene. NO also derives from l-arginine, 
and therefore, depletes the substrate for PA synthesis. It has microbicidal effects and reduces viral replication. Sod1 is an antioxidative molecule which resolves 
oxidative stress. For further details consult the text.
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(102). Spermine is generated from spermidine, which itself is 
produced from putrescine (Figure 3). Ornithine, which gener-
ates putrescine, is produced from l-arginine by arginase (103). 
Polyamines bind DNA, RNA, and proteins and are implicated 
in supporting transcription, translation, and deacetylation 
to influence a plethora of different cellular functions, includ-
ing proliferation, apoptosis, autophagy, and gene regulation 
(103). Spermidine–spermine acetyltransferase (SAT1 or SSAT) 
acetylates spermidine and spermine, which promotes either their 
conversion back to putrescine or their export from the cell (102, 
103). Interestingly, type I IFNs induce the expression of SAT1 
and, therefore, deplete spermidine and spermine levels (104). 
The depletion of these two polyamines has a strong antiviral 
effect and inhibits replication of the RNA viruses, Zika virus and 
Chikungunya virus (104). Mechanistically, polyamines seem to 
be important for transcription and translation of viral RNA and 
proteins. Limiting polyamine synthesis, therefore, emerges as a 
novel antiviral strategy and SAT1 constitutes an important ISG.
iFNs Stimulate Arginine-Dependent NO 
Production
NO is a gaseous and inorganic free radical best known for its 
vasodilatory and microbicidal effects (105). However, NO is also 
an important mediator in intracellular inhibition of viral replica-
tion, which results in lower viral yields and more efficient host 
clearance of the infection (106). NO is produced by the enzymatic 
modification of l-arginine to l-citrulline by NO synthases (NOS) 
(Figure 3). NOS type 2 (NOS2, iNOS) is an IFNγ-inducible pro-
tein in macrophages and requires IRF1 as a transcription factor, 
which itself is regulated by STAT1 (106, 107). Molecularly, the 
antiviral activities of NO are poorly described, but one demon-
strated mechanism is nitrosylation of viral molecules (108). For 
example, NO S-nitrosylates the cysteine residue in the active site 
of Coxsackievirus protease 3C, thus inhibiting protease activity 
and interrupting the viral life cycle (109). In addition, the genera-
tion of NO by NOS2 depletes the common substrate l-arginine 
and, subsequently reduces polyamine levels, as described above. 
Moreover, this relieves a feedback inhibition mechanism, because 
polyamines can directly inhibit NOS2 (110). Hence, IFN-induced 
NOS2 and SAT1 induction have antiviral effects due to a coordi-
nated shift from polyamine synthesis to NO production.
Type i iFNs Promote Oxidative Stress and 
Tissue Damage
Viral or bacterial infections often cause immunopathology and 
tissue damage, not only because of the pathogens destroying the 
tissue but because of an overactivation of the immune system, 
which promotes tissue destruction. For example, excessive type I 
and II IFN production can drive tissue damage by proinflamma-
tory actions on innate and adaptive immune cells, as well as the 
induction of apoptosis (111–113). IFNγ can cause the production 
of ROS, which induces apoptosis (114). NO contributes to tis-
sue damage, especially if substantial numbers of IFN-activated 
macrophages produce large micromolar quantities of NO (115). 
FiGURe 4 | interferon influences tryptophan metabolism to reprogram 
metabolism and inflammation. IDO1, which is induced by IFNs, catalyzes 
the production of Kyn from Trp. As many microorganisms rely on this amino 
acid, this represents a mechanism against bacterial infections. Furthermore, 
Trp is important for T-cells, and its depletion, therefore, inhibits T-cell effector 
immunity, while Kyn promotes T-cell tolerance by inducing Tregs. Depletion of 
Trp causes inhibition of mTOR complex 1 as well as MAP kinase-interacting 
kinases and, therefore, induces changes at the translational level of 
metabolism and inflammation. For further details consult the text.
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First, NO can have proinflammatory effects on other cells of the 
immune system causing hyperactivation and immunopathology 
(105). Moreover, NO can rapidly react with hydrogen peroxide 
(H2O2) to form peroxynitrite (ONOO−), which nitrates proteins 
and is highly toxic, leading to the accumulation of injurious intra-
cellular oxidants and to DNA damage (116). This NO-induced 
oxidative stress causes cytotoxicity, which promotes cellular and 
organ dysfunction (115). Currently, there is no clear-cut way of 
predicting whether NO has a more important role in viral clear-
ance or in tissue pathology for a particular viral pathogen.
There are additional metabolic mechanisms explaining how 
IFN signaling can promote immunopathology. Infection of 
mice with LCMV causes a dysregulation of the redox system 
in the liver. In this infection model, the early production of 
type I IFN causes tissue pathology due to the downregulation 
of superoxide dismutase 1 (Sod1) in the liver (117). Sod1 is a 
ubiquitously expressed antioxidative molecule, which can pro-
tect cells from oxidative stress by scavenging O2
−  radicals (118) 
(Figure 3). Hence, type I IFN-mediated oxidative stress may be 
a key mediator of virus-induced liver damage, and this suggests 
that early antioxidant treatment may be therapeutically helpful 
in ameliorating tissue damage. On the other hand, this oxida-
tive stress, induced by the downregulation of Sod1, may also be 
part of an immediate antioxidant host defense system against 
pathogens (117).
Depletion of Tryptophan as an 
immunomodulatory Mechanism of iFN
Indoleamine-2,3-dioxygenase 1 (IDO1) is an intracellular, non-
secreted enzyme, which catalyzes the production of kynurenine 
(Kyn) derivatives from the essential amino acid tryptophan (Trp) 
(119). The IDO1 promoter region contains two IFN-stimulated 
response elements and three IFNγ-activated sites. Hence, IFNγ is 
the most potent inducer of IDO1 expression in many cells, includ-
ing macrophages, fibroblasts, and pDCs (120, 121) (Figure  4). 
Although type I IFNs are able to directly induce IDO1, the 
maximum IDO1 expression requires co-stimulation with TNF-α 
or LPS (122, 123). Strong activation of IDO1 by IFNγ decreases 
serum levels of Trp. Since many microbial organisms rely on Trp, 
its degradation by IDO1-expressing cells of the innate immune 
system seems to be a major immune mechanism against bacterial 
infections (124). In fact, IFNγ-induced IDO1 expression seems to 
be protective in Toxoplasma gondii, Salmonella enterica serovar 
Typhi (S. Typhi), or Chlamydia pneumoniae infections (124, 
125). For example, IFNγ-primed macrophages effectively contain 
intracellular replication of S. Typhi depending on the activation 
of IDO1 (125).
IDO1 expression also plays an important role during viral 
infections, such as HIV, influenza, Epstein–Barr, HBV, and HCV 
(124, 126). However, in viral infections, the induction of IDO1 
by IFN seems to be generally harmful by the establishment of an 
immunotolerogenic microenvironment (124). Trp is important 
for activation and proliferation of T cells. Hence, Trp depletion 
inhibits T cell immunity and, moreover, the oxidation of Trp by 
IDO1 generates Kyn derivatives, which promote T cell tolerance 
by induction of regulatory T cells (121) (Figure  4). Therefore, 
mice lacking IDO1 exhibit significantly lower morbidity after sub-
lethal influenza A infection by generating a stronger influenza-
specific effector CD8 T cell response, though viral clearance rates 
are unaffected by IDO1 ablation (127). Similarly, genetic ablation 
of IDO1 or chemical inhibition with 1-methyl-d-l-tryptophan 
suppresses viral replication of murine leukemia virus in  vivo 
and upregulates type I IFN production (128). In conclusion, in 
various chronic infections, autoimmune diseases, and cancer, an 
increased expression of IDO1, besides its antiviral effects, may 
promote an immunosuppressive environment, which potentially 
contributes to disease (119, 121, 123, 125).
Tryptophan Depletion Suppresses  
mTOR-Mediated Translation and 
Modulates iFNγ-Dependent Metabolic 
Processes
The importance of translational control of many cellular 
responses, including metabolism, is increasingly appreciated 
(129, 130). On the one hand, type I IFNs cause massive trans-
lational inhibition as antiviral strategy (131), but on the other 
hand, they do promote the translation of ISGs, including PKR 
(10). Molecularly, AKT-mTORC1, mTORC2, and MAP kinase-
interacting kinases (MNK), as well as eukaryotic initiation factor 
4E (eIF4E) signaling are transiently activated by type I IFNs. An 
increase in ISG mRNA translation follows, which represents the 
early phase of IFN response (132–135). However, in primary 
human macrophages, stimulated by TLR2 ligands, IFNγ induces 
a strikingly different response. It reprograms metabolic path-
ways toward enhanced mitochondrial pathways and oxidative 
TABLe 1 | Metabolic changes caused by interferons (iFNs).
effects of iFNs Cell type Reference
Generally, IFNs cause a translational inhibition, but promote the transcription of IFN-stimulated genes (1, 4, 10, 12, 130, 
131–134)
↑Glucose uptake mouse embryonic fibroblasts, human plasmacytoid dendritic cells (pDCs) (31, 40)
↑Glycolysis Splenic CD11c+ MHCII+ DCs ex vivo, macrophages, human squamous carcinoma 
cell line
(32, 34, 35, 43)
↑Aerobic glycolysis Macrophages (33)
↓Oxidative phosphorylation and adenosine triphosphate 
(ATP) production
Human squamous carcinoma cell line, mouse L929 or human Daudi cells, human 
CD4+ T cells ex vivo, pDCs
(35–37, 40)
↑Oxidative phosphorylation and ATP production Primary human macrophages, peripheral blood mononuclear cells, pDCs, 
conventional DCs, keratinocytes, or memory T cells
(39, 135, 136)
↑Lipolysis Adipocytes of mice in vivo (41)
↑Itaconic acid Alveolar macrophages (47)
↑NO, reactive oxygen species Macrophages, primary hepatocytes, macrophages (30, 33, 113, 114)
↓Fatty acid and cholesterol synthesis HeLa cells (86)
↑25-hydroxycholesterol Macrophages (88)
↑Membrane rigidity Daudi cells, L9292 cells, human monocytes, RSa, RSb, IF r and RD-114 cells, red 
blood cells of patients with hepatitis C infection
(91–95)
↓polyamine synthesis Huh7 cells, BHK-21 cells (103)
↑IDO1 expression, ↓of tryptophan Macrophages, fibroblasts, pDCs, Toxoplasma gondii, Salmonella enterica serovar 
Typhi (S. Typhi), or Chlamydia pneumoniae infections
(119, 120, 123, 124)
↑AKT–mTOR complex 1, mTORC2, MAP kinase-
interacting kinases, eukaryotic initiation factor 4E
Huh-7, Huh-7.5, 293T, MT-4, STAT1−/− Fib, reviewed in, MEFs (131–134)
↓Translation of repressors of inflammation Human macrophages (135, 138) (135, 138)
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phosphorylation by inhibition of mTORC1 as well as MNK (136) 
(Figure 4). IFNγ treatment of patients with sepsis also enhances 
mitochondrial oxidative phosphorylation in peripheral blood 
mononuclear cells (137). mTORC1 and mTORC2 are well-
known to control a wide array of metabolic pathways, including 
glycolysis, oxidative phosphorylation, and lipid metabolism (5, 
138). Moreover, IFNγ suppresses the translation of repressors of 
inflammation, including HES1, HEY1, and IκBα, via mTORC1 
in human macrophages (136, 139). The translational inhibition 
of these molecules promotes an inflammatory response and may 
contribute to the potent proinflammatory effects of this cytokine 
(140). Similarly, diminishing translation by blocking mTORC1 
with rapamycin favors the translation of the more abundant pro-
inflammatory cytokines such as IL-12 and blocks the translation 
of low abundant mRNAs such as IL-10 (5, 141). Mechanistically, 
IFNγ induces IDO1 expression (as explained above) by depleting 
intracellular tryptophan levels, and this suppresses mTORC1 
(136). The amino acids leucine, arginine, as well as tryptophan are 
sensed by mTORC1 at the level of the lysosome. Only if sufficient 
amino acids are present, full mTORC1 activation by growth fac-
tors or PRR ligands occurs (142, 143). Additionally, IFNγ inhibits 
expression of the macrophage colony-stimulating factor receptor 
and interferes with the expression of SIRT1, a major deacetylase 
that influences energy metabolism and longevity (136, 144). 
Together, these data indicate that both the control of the cellular 
metabolism and mTORC1 activation by IFNγ may be central 
mediators of this pleiotropic proinflammatory molecule.
CONCLUDiNG ReMARKS
Based on recent and older studies, a theme is emerging, which 
shows that IFNs are potent modulators of basic cellular processes 
(Table  1). Viruses rewire the metabolism of the host cell to 
efficiently replicate and produce infectious particles. Therefore, 
interfering with distinct metabolic pathways seems to constitute 
one of the core antiviral properties of IFNs. In this context, we 
described that inhibition of FA and cholesterol synthesis as well 
as induction of NO are to date the best studied metabolic actions 
of IFNs. Future studies should focus on expanding the investiga-
tion of the influence of IFNs on the cellular energy metabolism 
including FAO. Moreover, IFN-mediated metabolic effects may 
be mediated by metabolic-derived protein and epigenetic modi-
fications such as N-glycosylation, methylation, or acetylation (44, 
145, 146).
However, some considerations need to be taken into account 
when studying metabolic processes. First, the metabolism of 
immortalized cell lines may be notably different from that 
of primary cells. Proliferating cell lines harbor mutations 
in pathways that regulate metabolic processes such as the 
mTOR pathway and already show a Warburg effect to allow 
infinite proliferation. Moreover, the composition of the cell 
culture medium profoundly affects the cellular metabolism. 
Culture media often contain nutrients that far exceeds the 
amounts observed in tissues and thus may mask the impor-
tance of individual metabolic pathways for specific immu-
nologic functions. Finally, pharmacological inhibitors are 
instrumental in metabolic studies (147), but they may show 
off-target effects and should, therefore, be complemented with 
genetic studies to elucidate whether an observed metabolic 
shift is the cause or the consequence of a change in the cellular 
phenotype (148).
The expansion of our knowledge on immunometabolism and 
the role of IFNs suggest novel avenues for metabolic therapies. 
In this regard, it might be possible in the future to target specific 
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pathways that are critical for viral replication, such as FAS or 
cholesterol synthesis. More generally, distinct immune cells may 
be more dependent on specific metabolic processes than others, 
and hence, more vulnerable to allow specific immunometabolic 
targeting of cells in  vivo (149, 150). Moreover, the support of 
antiviral actions of IFNs by providing metabolites may also be 
possible. In conclusion, the reciprocal regulation of IFNs and 
metabolic processes advances our understanding of immunome-
tabolism and may hold future surprises for our understanding of 
immunity in health and disease.
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